We’re thrilled to announce a groundbreaking collaboration with Bayer to integrate Segmed’s real-world imaging data (RWiD) solution into Bayer’s AI Innovation Platform (AIIP). Together, we aim to accelerate the development of AI-powered healthcare solutions that benefit radiologists and patients alike.
💡 What does this mean?
With access to 100 million diverse, de-identified imaging studies via Segmed, Bayer’s platform will empower researchers, developers, and healthcare innovators to:
🔹 Build scalable and compliant AI medical imaging tools
🔹 Tackle the growing imaging workloads faced by radiologists
🔹 Advance patient outcomes through cutting-edge solutions
Dr. Martin Willemink, MD PhD FSCCT, our Co-founder and CEO, shares:
"Being part of an end-to-end AI developer environment has been a key vision since we founded Segmed. Through this collaboration, we’ll help healthcare organizations efficiently tap into fit-for-purpose data, ultimately improving patient outcomes."
We sincerely thank Bayer for trusting Segmed as a partner in this journey to advance innovation in medical imaging and improve patient care worldwide.
This partnership combines Segmed’s expertise in de-identified imaging data with Bayer’s leadership in healthcare innovation, regulatory know-how, and clinical excellence. Together, we’re driving real impact in healthcare by reducing costs, supporting radiologists, and advancing patient care.
💻 Learn more about Segmed’s mission and our cutting-edge solutions at https://www.segmed.ai/
#AIinHealthcare #RealWorldData #MedicalImaging #Innovation #SegmedAI #TeamBayer #Collaboration #PatientCare #BayerInRadiology
